Real-world clinical outcomes in patients with biochemical recurrence after local therapy for non-metastatic prostate cancer
{{output}}
Aims: We assessed the proportion of patients with biochemical recurrence (BCR), the occurrence of BCR in risk groups according to prostate-specific antigen doubling time (PSA-DT), and clinical outcomes in risk groups. ... ...
